SELECT FROM MENU

Therapy Areas
Drug Classes

       Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Advanced NSCLC

Advanced NSCLC

SCLC

SCLC

Biomarkers

Biomarkers

       Drug Classes

Targeted Therapies

Targeted Therapies

Immunotherapies

Immunotherapies

ADCs

ADCs

Advanced NSCLCOctober 1, 2026

Uncommon EGFR exon 19 deletions were associated with shorter PFS on osimertinib in a 111-patient study

Uncommon EGFR exon 19 deletion subtypes were associated with shorter progression-free survival on osimertinib than the common E746_A750del deletion, in a multicentre retrospective study published in Lung Cancer, with the L747_A750delinsP subtype standing out as potentially high risk.
Share

In brief

  • In a multicentre retrospective study of 111 patients with advanced EGFR exon 19 deletion-positive NSCLC treated with osimertinib, 86.5% received the drug as first-line therapy.
  • Patients with deletions other than E746_A750del (n=25) had a shorter median progression-free survival (PFS) than those with E746_A750del (n=86): 14.3 vs 20.6 months, p<0.05.
  • The four patients with L747_A750delinsP had a median PFS of 3.5 months and a median overall survival (OS) of 11.8 months, against 20.6 and 48.5 months with E746_A750del (both p<0.001).
  • In public genomic databases, non-E746_A750del deletions carried more RBM10 co-mutations.
  • L747_A750delinsP was characterised by frequent CDKN2A/B homozygous deletions and MYC amplifications.

Study at a glance

  • Design: multicentre retrospective cohort, with genomic analysis of AACR Project GENIE and MSK-CHORD data
  • Population: 111 patients with advanced EGFR exon 19 deletion-positive NSCLC
  • Treatment: osimertinib, first line in 86.5%
  • Groups: E746_A750del (n=86) and other exon 19 deletions (n=25), including L747_A750delinsP (n=4)
  • Median PFS: 20.6 months (E746_A750del) vs 14.3 months (other deletions), p<0.05
  • L747_A750delinsP (n=4): median PFS 3.5 months, median OS 11.8 vs 48.5 months with E746_A750del (both p<0.001)
  • Co-alterations: RBM10 in non-E746_A750del; CDKN2A/B homozygous deletion and MYC amplification in L747_A750delinsP
  • Not reported: hazard ratios, adjustment for other prognostic factors, and OS for the non-E746_A750del group as a whole (in the abstract)

Exon 19 deletions differ, and osimertinib data by subtype are scarce

E746_A750del is the most frequent of the EGFR exon 19 deletions, and the authors set out to test whether the rarer variants behave differently on osimertinib, for which subtype-level evidence has been limited.

Differences in survival between exon 19 deletion subtypes have been suggested after treatment with EGFR tyrosine kinase inhibitors. The authors note that the biological mechanisms behind any such difference are poorly understood, which is why the study pairs its clinical cohort with a genomic analysis.

A 6-month shorter median PFS with the less common deletions

Median PFS was 14.3 months in the 25 patients whose tumours carried a deletion other than E746_A750del, compared with 20.6 months in the 86 patients with E746_A750del (p<0.05).

Most of the cohort (86.5%) received osimertinib as first-line therapy, so the comparison largely reflects the setting in which the drug is now standard. The design is retrospective, the smaller group has 25 patients, and the abstract gives the result as p<0.05 without an exact value.

L747_A750delinsP: a median PFS of 3.5 months in four patients

Compared with E746_A750del, the delinsP subtype had a median PFS of 3.5 versus 20.6 months and a median OS of 11.8 versus 48.5 months, both with p<0.001.

The size of the gap is large, and it rests on four patients. The authors describe L747_A750delinsP as potentially a high-risk subtype, and that qualification matches the evidence: a finding of this size in so small a group needs confirmation in a larger series before it could inform treatment decisions.

RBM10 co-mutations in the uncommon deletions, CDKN2A/B loss and MYC gain in delinsP

These co-alterations come from whole-exome sequencing data in the AACR Project GENIE registry and the MSK-CHORD real-world dataset, not from the treated cohort itself.

Non-E746_A750del deletions showed a higher rate of RBM10 co-mutations. L747_A750delinsP was characterised by frequent CDKN2A/B homozygous deletions and MYC amplifications. The authors conclude that differences in co-occurring genomic alterations may contribute to the prognostic heterogeneity among exon 19 deletion subtypes. Because the genomic findings come from public databases rather than the treated cohort, that link remains a hypothesis.

Sources

  1. Lung Cancer. Clinical outcomes and genomic features of uncommon EGFR exon 19 deletion subtypes in osimertinib-treated non-small cell lung cancer (2026-08-31). doi.org

Featuring Lung Summit faculty

This study was co-authored by Lung Summit faculty Hidehito Horinouchi.

This article was produced independently by the Lung Summit editorial team, without industry funding or input.

i 3 On This Page

Share

       Continue With

Related Topics

Videos
Jacob Sands, Solange Peters and Martin Reck
Dec102026
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2026 Year in Review

Learn more about the event

S. PetersJ. SandsM. Reck
Nov 13 2026
ILCS 2026
Advanced NSCLCResectable NSCLCSCLC

Panel: open questions & patient cases

Nov 13 2026
ILCS 2026
Advanced NSCLC

New compounds and combinations for non-oncogene-addicted advanced NSCLC

A. Cortellini
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCResectable NSCLCTargeted Therapies

One Backbone, Many Opportunities: Osimertinib Across the EGFRm NSCLC Journey

M. Hochmair
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

First-Line NSCLC in Transition: Opportunities and Challenges for KRAS G12C

A. Curioni-Fontecedro
Nov 13 2026
ILCS 2026
Advanced NSCLCADCs

The ADC wave: integrating new agents in NSCLC

D. Planchard
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Targeting (K)RAS with new compounds

C. Lovly
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Other actionable genomic alterations, incl. HER2 and ROS1

T. Sequeira
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

New standards in EGFR- and ALK-positive NSCLC

H. Horinouchi
Oliver Gautschi on EGFR+ NSCLC
Jul 20 2026
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi

Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.

O. Gautschi
Prof. Alessandra Curioni-Fontecedro discussing approaches in metastatic PD-L1 negative NSCLC
May 04 2026
SPONSORED INTERVIEW
Advanced NSCLCImmunotherapies

Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro

Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.

A. Curioni-Fontecedro
Lung Cancer Review by Solange Peters, Martin Reck, Charles Rudin
Dec 18 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2025 Approvals & Highlights

} 1 h 49 min

S. PetersC. RudinM. Reck
Sep 26 2025
ILCS 2025
Advanced NSCLC

Latest Options for Non-Oncogene Addicted Advanced NSCLC in Frontline and Beyond

} 32 min

A. Curioni-Fontecedro
Sep 26 2025
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Latest Advances in Frontline EGFR+ NSCLC

} 14 min

A. Curioni-Fontecedro
Sep 26 2025
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

Unlocking New Potentials in EGFR-Mutant NSCLC

} 30 min

A. Passaro
Sep 26 2025
ILCS 2025
Targeted Therapies

DEBATE: Which Is the Better Choice in EGFR+ Advanced NSCLC?

} 31 min

T. Newsom-DavisX. Le
Sep 26 2025
ILCS 2025
Targeted Therapies

Actionable Genomic Alterations – Including HER2 and MET

} 26 min

S. Saw
Sep 26 2025
ILCS 2025
Targeted Therapies

Targeting EGFR and ALK in NSCLC

} 26 min

T. John
Sep 26 2025
ILCS 2025
Advanced NSCLC

Open Discussion on Patient Cases

} 22 min

Targeted Therapies by Oliver Gautschi, Jarushka Naidoo, Nicolas Girard
Jul 10 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCTargeted Therapies

Targeted Therapies in NSCLC

} 1h 30 min

O. GautschiJ. NaidooN. Girard
Articles
Nov 16 2026
RESEARCH
Advanced NSCLCResectable NSCLC

South Asian experts agree consensus recommendations for NSCLC, with low-cost options built in

V. Noronha
Nikolaj Frost
Nov 15 2026
RESEARCH
Advanced NSCLCResectable NSCLC

A 454-patient single-cell atlas links NSCLC tumour cell states to metastasis and survival

N. Frost
Charles Rudin
Nov 14 2026
RESEARCH
Advanced NSCLCSCLCTargeted Therapies

SCLC transformation in 5 of 11 patients given first-line osimertinib with platinum and etoposide

C. Rudin
Nov 14 2026
RESEARCH
Advanced NSCLCBiomarkersADCs

Membrane share of TROP2 identified longer PFS on Dato-DXd in nonsquamous NSCLC

J. SandsM. PérolN. Girard
Nov 12 2026
RESEARCH
BiomarkersResectable NSCLCTargeted Therapies

MTAP loss seen in 17% of NSCLC by immunohistochemistry, with PRMT5 inhibitors active in TKI-resistant cells

Z. Piotrowska
Nov 04 2026
RESEARCH
Advanced NSCLCImmunotherapies

Local ablative therapy alone after durvalumab was followed by an mOS of 18.7 months in oligoprogressive NSCLC

A. FilippiL. Hendriks
Nov 01 2026
RESEARCH
Advanced NSCLCBiomarkersTargeted Therapies

Secondary ALK resistance mutations found in 8% of ALK-positive NSCLC samples on genomic profiling

P. Hofman
Oct 31 2026
RESEARCH
Advanced NSCLCTargeted Therapies

VTE reporting in fusion-positive NSCLC trials is fragmented across publications and registries

A. Cortellini
Martin Reck
Oct 30 2026
RESEARCH
Advanced NSCLCResectable NSCLCImmunotherapies

Neoadjuvant durvalumab plus chemotherapy led to resection in 74.6% of patients in the MDT-BRIDGE trial

M. ReckN. GirardA. Filippi
Oct 29 2026
RESEARCH
Advanced NSCLCImmunotherapies

Adding chemotherapy to pembrolizumab lengthened PFS in PD-L1-high advanced NSCLC in PERSEE

M. Pérol
Oct 26 2026
INDUSTRY NEWS
Advanced NSCLCResectable NSCLCTargeted Therapies

Divarasib extended OS over sotorasib or adagrasib in previously treated KRAS G12C-mutated NSCLC

Oct 22 2026
RESEARCH
Advanced NSCLC

TP53 Y220C occurs in 0.7% of NSCLC and more often in EGFR-mutant tumours, in an ETOP study of 28,244 patients

R. StahelL. BubendorfL. HendriksS. PetersS. Finn
Oct 21 2026
SPONSORED
Advanced NSCLCImmunotherapies

The “tail of the curve” is real: long-term survival in PD-L1–negative metastatic NSCLC

A. Curioni-Fontecedro
Oct 21 2026
RESEARCH
Advanced NSCLCBiomarkersResectable NSCLC

ctDNA on immunotherapy is prognostic across NSCLC stages, but ctDNA-guided treatment remains investigational

U. Malapelle
Oct 19 2026
RESEARCH
Advanced NSCLCImmunotherapies

Nivolumab plus ipilimumab in 545 Japanese patients with metastatic NSCLC: the LIGHT-NING 2.5-year update

H. Horinouchi
Oct 18 2026
RESEARCH
Advanced NSCLCTargeted Therapies

First-line firmonertinib produced responses in 68% of patients with EGFR PACC-mutant NSCLC at 240 mg

X. LeD. PlanchardM. Pérol
Oct 16 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Platinum-pemetrexed after selective RET inhibitor failure gave a median real-world PFS of 6.1 months

A. CallesJ. RemonA. CortelliniD. PlanchardB. Ricciuti
Oct 16 2026
RESEARCH
Advanced NSCLC

Fixation protocol determined immunocytochemistry performance on lung cancer cytology slides in an IASLC study

L. Bubendorf
Oct 15 2026
NEWS
Resectable NSCLC

A papal diagnosis turns the world’s attention to its most diagnosed cancer

Oct 14 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Durable responders to immunotherapy for NSCLC or melanoma mostly reported good health, but frequent fatigue

N. Girard